Compounds > 1,2,3,4-tetrahydro-7,12-dimethylbenz(a)anthracene
Page last updated: 2024-12-06
1,2,3,4-tetrahydro-7,12-dimethylbenz(a)anthracene
**1,2,3,4-Tetrahydro-7,12-dimethylbenz(a)anthracene (DMBA)** is a potent polycyclic aromatic hydrocarbon (PAH) that is known to be a powerful carcinogen.
**Structure and Properties:**
* **Structure:** DMBA is a planar molecule with four fused benzene rings and two methyl groups attached at positions 7 and 12.
* **Properties:** It is a white crystalline solid that is poorly soluble in water but soluble in organic solvents.
**Carcinogenic Activity:**
DMBA is a highly potent and potent carcinogen, primarily affecting the skin and mammary glands. Its carcinogenic activity stems from its ability to:
* **Bind to DNA:** DMBA can bind to DNA, forming adducts that disrupt DNA replication and gene expression.
* **Generate reactive oxygen species (ROS):** DMBA can induce the formation of ROS, which can damage cellular components and contribute to tumor development.
**Research Importance:**
DMBA plays a crucial role in research as a model compound for studying:
* **Carcinogenesis:** It serves as a standard model for investigating the mechanisms of cancer development, particularly skin and breast cancer.
* **DNA damage and repair:** DMBA-induced DNA damage provides a valuable tool for studying DNA repair pathways and the role of DNA repair in cancer prevention.
* **Cellular signaling pathways:** DMBA can activate various signaling pathways involved in cell proliferation, differentiation, and apoptosis, providing insights into cancer cell behavior.
* **Environmental toxicology:** DMBA is found in environmental pollutants, such as smoke and tar, and serves as a model for studying the carcinogenic effects of PAHs.
**Applications in Research:**
DMBA is used in a variety of research settings, including:
* **Animal models:** DMBA is frequently used to induce skin tumors in mice and rats.
* **Cell culture studies:** DMBA can be applied to cultured cells to investigate its effects on DNA damage, cell cycle regulation, and gene expression.
* **Drug development:** DMBA-induced tumors provide a platform for testing the efficacy of anticancer drugs and preventative agents.
**Conclusion:**
1,2,3,4-Tetrahydro-7,12-dimethylbenz(a)anthracene (DMBA) is a potent carcinogen that plays a significant role in research related to cancer development, DNA damage, and environmental toxicology. Its ability to induce tumors and alter cellular processes makes it a valuable tool for studying cancer mechanisms and developing new treatments.
Cross-References
ID Source | ID |
PubMed CID | 49724 |
CHEMBL ID | 319383 |
MeSH ID | M0102909 |
Synonyms (12)
Synonym |
CHEMBL319383 |
1,2,3,4-tetrahydro-7,12-dimethylbenz(a)anthracene |
benz(a)anthracene, 1,2,3,4-tetrahydro-7,12-dimethyl- |
brn 3317395 |
7,12-dimethyl-1,2,3,4-tetrahydrobenz(a)anthracene |
1,2,3,4-tetrahydro-dmba |
th-dmba |
7,12-dimethyl-1,2,3,4-tetrahydrobenzo[a]anthracene |
67242-54-0 |
4-05-00-02449 (beilstein handbook reference) |
DTXSID20217577 |
1,2,3,4-tetrahydro-7,12-dimethylbenz[a]anthracene |
Bioassays (6)
Assay ID | Title | Year | Journal | Article |
AID200692 | Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA 100 strain) in absence of S9 fraction | 1980 | Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
| Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene. |
AID200698 | Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA1537 strain) in absence of S9 fraction | 1980 | Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
| Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene. |
AID200700 | Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA1537 strain) in presence of S9 fraction | 1980 | Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
| Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene. |
AID200694 | Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA 100 strain) in presence of S9 fraction | 1980 | Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
| Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene. |
AID200697 | Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA 98 strain) in presence of S9 fraction | 1980 | Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
| Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene. |
AID200695 | Mutagenic activity by measuring net reverent colonies per 10 ug of compound with Salmonella Typhimurium (TA 98 strain) in absence of S9 fraction | 1980 | Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
| Synthesis and mutagenicity of A-ring reduced analogues of 7,12-dimethylbenz[a]anthracene. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 4 (57.14) | 18.7374 |
1990's | 3 (42.86) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.21
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.21 (24.57) | Research Supply Index | 2.20 (2.92) | Research Growth Index | 4.40 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |